Wahed Zedan

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Corrigendum to "Impact of site-specific conjugation strategies on the pharmacokinetics of antibody-conjugated radiotherapeutics" [Eur J Med Chem. 2024 Dec 15; 280:116927. doi: 10.1016/j.ejmech.2024.116927. PMID: 39378827].

Corrigendum to "Impact of site-specific conjugation strategies on the pharmacokinetics of antibody-conjugated radiotherapeutics" [Eur J Med Chem. 2024 Dec 15; 280:116927. doi: 10.1016/j.ejmech.2024.116927. PMID: 39378827].

Journal: European journal of medicinal chemistry
Published: January 20, 2026

Fractionation gives therapeutic benefit in animal model of [177Lu]Lu-PSMA-617 therapy of prostate cancer.

Fractionation gives therapeutic benefit in animal model of [177Lu]Lu-PSMA-617 therapy of prostate cancer.

Journal: EJNMMI research
Published: January 06, 2026

Key Regulatory Elements of the TGFβ-LRRC15 Axis Predict Disease Progression and Immunotherapy Resistance Across Cancer Types.

Key Regulatory Elements of the TGFβ-LRRC15 Axis Predict Disease Progression and Immunotherapy Resistance Across Cancer Types.

Journal: bioRxiv : the preprint server for biology
Published: December 09, 2024

Intratumoral Distribution of [177Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate Cancer.

Intratumoral Distribution of [177Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate Cancer.

Journal: Cancer biotherapy & radiopharmaceuticals
Published: November 28, 2024

Optimizing peptide nucleic acid-based pretargeting for enhanced targeted radionuclide therapy.

Optimizing peptide nucleic acid-based pretargeting for enhanced targeted radionuclide therapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: August 27, 2024

Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance.

Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance.

Journal: Signal transduction and targeted therapy
Published: August 01, 2024

Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics.

Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics.

Journal: European journal of medicinal chemistry
Published: July 09, 2024

Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [177Lu]Lu-PSMA-617 therapy in an animal model of prostate cancer.

Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [177Lu]Lu-PSMA-617 therapy in an animal model of prostate cancer.

Journal: American journal of nuclear medicine and molecular imaging
Published: March 15, 2023

Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response.

Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response.

Journal: Molecular cancer research : MCR
Published: September 16, 2022

Single-cell quantification and dose-response of cytosolic siRNA delivery.

Single-cell quantification and dose-response of cytosolic siRNA delivery.

Journal: Nature communications
Published: October 14, 2021

A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen.

A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen.

Journal: Cancers
Published: April 30, 2021

177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging.

177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging.

Journal: Biomolecules
Published: January 13, 2021
Showing 1-12 of 12

Last Updated: 09/26/2026